Retatrutide Shows Promise for Diabetes, Obesity, and Chronic Kidney Disease

The global burden of Type 2 Diabetes and Obesity continues to rise, often leading to severe complications like Chronic Kidney Disease (CKD). Managing these interconnected conditions is complex, requiring therapies that address multiple metabolic pathways without exacerbating renal issues. Current treatments often focus on single aspects, leaving a significant need for comprehensive solutions. This systematic review and meta-analysis addresses the critical knowledge gap regarding the aggregated efficacy and safety profile of Retatrutide in patients simultaneously suffering from diabetes and/or obesity comorbid with CKD.

The meta-analysis revealed significant and consistent benefits of Retatrutide across metabolic and renal parameters. Patients treated with Retatrutide experienced a substantial reduction in HbA1c by an average of -1.9% (95% CI: -2.1% to -1.7%, p<0.001) compared to placebo or active comparators. Body weight was also significantly reduced, with an average -16.2% decrease from baseline (95% CI: -17.5% to -14.9%, p<0.001). The most impactful finding was the significant improvement in renal markers, including a 35% reduction in albuminuria (urinary albumin-to-creatinine ratio, p<0.001) and a stabilization or slight increase in estimated glomerular filtration rate (eGFR) by +4.8 mL/min/1.73m² (95% CI: +3.5 to +6.1, p<0.001) compared to control groups. The safety profile was consistent with previous findings, primarily involving mild-to-moderate gastrointestinal adverse events, with no significant increase in serious adverse events related to renal function.